Immunovia AB (LTS:0G8X) Change In Payables And Accrued Expense : kr0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Immunovia AB Change In Payables And Accrued Expense?

Immunovia AB's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was kr0.00 Mil. It means Immunovia AB's Accounts Payable & Accrued Expense stayed the same from Dec. 2024 to Mar. 2025 .

Immunovia AB's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was kr0.00 Mil. It means Immunovia AB's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Dec. 2024 .

Immunovia AB Change In Payables And Accrued Expense Historical Data

The historical data trend for Immunovia AB's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovia AB Change In Payables And Accrued Expense Chart

Immunovia AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Immunovia AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Immunovia AB Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

Immunovia AB Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Immunovia AB's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunovia AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (LTS:0G8X) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

IMMNOV:Sweden 1YR:Germany

Address

Medicon Village, Scheelevagen 8, Lund, SWE, 223 63

Website

https://www.immunovia.com

Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.

Immunovia AB Headlines

No Headlines